Determination of HER2 amplification by in situ hybridization: When should chromosome 17 also be determined?

American Journal of Clinical Pathology

Volumn 130, Issue 6, 2008, Pages 920-926

  Bartlett, John M S ^a   Campbell, Fiona M ^a   Mallon, Elizabeth A ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

Amplification; Aneusomy; Breast; Chromosome 17; Copy number; FISH; Fluorescence in situ hybridization; HER2; In situ hybridization; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CHROMOSOME 17; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; ENZYME ASSAY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ANEUPLOIDY; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; DIAGNOSTIC ERRORS; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE;

EID: 58049212010     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPSDG53BEANCYE     Document Type: Article

References (20)

1. Walker RA, Bartlett JMS, Dowsett M, et al. HER2 testing in the UK: further update to recommendations J Clin Pathol. 2008;61:818-824.
2. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
3. Bartlett JMS. Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy. Am J Pharmacogenomics. 2005;5:303-315.
4. Faratian D, Bartlett J. Predictive markers in breast cancer: the future. Histopathology. 2008;52:91-98.
5. Bartlett JMS, Ellis IO, Dowsett M, et al. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER)-negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol. 2007;28:4423-4430.
6. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003;199:411-417.
7. Bartlett JMS, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195:422-428.
8. Ellis IO, Dowsett M, Bartlett J, et al. Recommendations for HER2 testing in the UK. J Clin Pathol. 2000;53:890-892.
9. Ellis IO, Bartlett J, Dowsett M, et al. Best Practice No. 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004;57:233-237.
10. Dowsett M, Hanby AM, Laing R, et al. HER2 testing in the UK: consensus from a national consultation. J Clin Pathol. 2007;60:685-689.
11. Hanna W, O'Malley FP, Barnes P, et al. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol. 2007;14:149-153.
12. Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol. 2003;199:418-423.
13. Bartlett JMS, Ibrahim M, Miller K, et al. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme. J Clin Pathol. 2007;60:816-819.
14. Dietel M, Ellis IO, Höfler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007;451:19-25.
15. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast cancer. Breast Cancer Res Treat. 2003;77:109-114.
16. Bartlett JMS, Watters AD, Ballantyne SA, et al. Is chromosome 9 loss a marker of disease recurrence in transitional cell carcinoma of the urinary bladder? Br J Cancer. 1998;77:2193-2198.
17. Bartlett JMS, Adie L, Watters AD, et al. Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy. BJU Int. 1999;84:775-779.
18. Watters AD, Ballantyne SA, Going JJ, et al. Aneusomy of chromosomes 7 and 17 predicts the recurrence of transitional cell carcinoma of the urinary bladder. BJU Int. 2000;85:42-47.
19. Watters AD, Going JJ, Grigor KM, et al. Progression to detrusor-muscle invasion in bladder carcinoma is associated with polysomy of chromosomes 1 and 8 in recurrent pTa/pT1 tumours. Eur J Cancer. 2002;38:1593-1599.
20. Wilde-Mathews A. Bad cancer tests drawing scrutiny. The Wall Street Journal. January 4, 2008:B1.